The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2009Validation of Nurr1 as a Drug Target for the Treatment of PD
Objective/Rationale:
Pharmacological methods to prevent or delay the degeneration of dopaminergic neurons in Parkinson’s disease (PD) are not available. We propose that Nurr1, a protein found in these... -
Target Validation, 2009Validation of Cyclophilin D, a Protein Involved in the Mitochondrial Permeability Transition, as a Target for Parkinson's Disease Therapy
Objective/Rationale:
Mitochondria dysfunction has long been proposed to contribute to the pathogenesis of Parkinson’s Disease. In addition to their role in ATP production, mitochondria play an... -
Therapeutics Development Initiative, 2009Dose-Response Assessment of ReS9-S7, a First-in-Class, Disease-modifying Drug Candidate for Treatment of Parkinson's Disease
Objective/Rationale:
ReS9-S7, a novel disease-modifying drug candidate directed against alpha-synuclein instigated neuronal toxicity, is planned to enter clinical Phase I studies in 2009/2010... -
Therapeutics Development Initiative, 2009Effect of Novel Neuronal Nicotinic Receptor Compounds on Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
Objective/Rationale:
The idea that compounds targeting neuronal nicotinic receptors may be useful for the treatment of L-dopa-induced abnormal involuntary movements (AIMs), or dyskinesias, stemmed from... -
Therapeutics Development Initiative, 2009Validation of LRRK2 as a Drug Target for Treatment of Parkinson's Disease Using Antisense Technology
Objective/Rationale:
Missense mutations in leucine-rich repeat serine/threonine-protein kinase (Lrrk2) are linked/associated with dominantly inherited, late-onset Lewy body Parkinson's disease (PD)... -
Therapeutics Development Initiative, 2009Pre-clinical Development of a Parkinson's Disease Therapy Using a Glucagon-Like Peptide (GLP)-1 Receptor Agonist
Objective/Rationale:
The Glucagon-Like-Peptide-1 (GLP-1) receptor agonist, exendin-4 (exenatide injection; brand name Byetta) is an FDA-approved, first-in-class treatment for patients with Type 2...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.